dpp 4 inhibitors and glp 1 agonists together Role of DPP-4 in Clinical Practice Frontiers | DPP-4 inhibitors for
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] [62].Qian P, Tian H, Wang Y, Lu W, Li Y, Ma T, et al
They are now shaping how clinicians manage weight, cardiovascular disease, and renal risk in patients with type 2 diabetes and obesity
As a result, GLP-1RAs show great promise as obesity treatments [114]
More companies are incorporating these medications into their treatment programs, but given that this is a new landscape with both proven and emerging uses, companies must measure vital signs, monitor secondary effects, and integrate behavior change into their care plans as they transition patients off these drugs over time
Is there a risk to (or for) pregnancies
